Antiviral Stewardship in Transplantation

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2025 Jan 8

PMID 39772192

Authors

Sruthi Bonda

Sonya Trinh

Jonathan Hand

Affiliations

Soon will be listed here.

Abstract

Though antimicrobial stewardship programs (ASPs) are required for hospitals, the involvement of transplant recipients in programmatic interventions, protocols, and metrics has historically been limited. Though there is a growing interest in studying stewardship practices in transplant patients, optimal practices have not been clearly established. A component of ASPs, antiviral stewardship (AVS), specifically targeting cytomegalovirus (CMV), has been more recently described. Understanding AVS opportunities and interventions is particularly important for transplant recipients, given the morbidity and mortality associated with viral infections, challenging clinical syndromes, ultrasensitive molecular diagnostic assays, antiviral resistance, and costs of viral disease and medications, as well as antiviral drug toxicities. This review highlights opportunities for AVS for CMV, EBV, HSV, VZV, SARS-CoV-2, respiratory syncytial virus, and BK polyomavirus in transplant patients.

References

Tansarli G, Chapin K . Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis. Clin Microbiol Infect. 2019; 26(3):281-290. DOI: 10.1016/j.cmi.2019.11.016. View

Fisher C, Knudsen J, Lease E, Jerome K, Rakita R, Boeckh M . Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clin Infect Dis. 2017; 65(1):57-63. PMC: 5848370. DOI: 10.1093/cid/cix259. View

Barlam T, Cosgrove S, Abbo L, MacDougall C, Schuetz A, Septimus E . Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016; 62(10):e51-77. PMC: 5006285. DOI: 10.1093/cid/ciw118. View

Duong A, Sweet A, Jain R, Hill J, Pergam S, Boeckh M . Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2019; 75(3):775-777. PMC: 7021092. DOI: 10.1093/jac/dkz499. View

Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H . Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2006; 44(2):245-9. DOI: 10.1086/509930. View

Kotton C, Kamar N, Wojciechowski D, Eder M, Hopfer H, Randhawa P . The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation. Transplantation. 2024; 108(9):1834-1866. PMC: 11335089. DOI: 10.1097/TP.0000000000004976. View

Kleiboeker H, Wang J, Borkowski N, Miner B, Prom A, Paplaczyk K . Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients. Transpl Infect Dis. 2024; 26(5):e14337. DOI: 10.1111/tid.14337. View

Wang N, Athans V, Neuner E, Bollinger J, Spinner M, Brizendine K . A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients. Transpl Infect Dis. 2018; 20(6):e12991. DOI: 10.1111/tid.12991. View

Tamura T, Choudhary M, Deo R, Yousuf F, Gomez A, Edelstein G . Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024; 7(9):e2435431. PMC: 11425144. DOI: 10.1001/jamanetworkopen.2024.35431. View

10.

Withers B, Blyth E, Clancy L, Yong A, Fraser C, Burgess J . Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2018; 1(24):2193-2205. PMC: 5737128. DOI: 10.1182/bloodadvances.2017010223. View

11.

Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D . Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002; 99(4):1159-64. DOI: 10.1182/blood.v99.4.1159. View

12.

Styczynski J, van der Velden W, Fox C, Engelhard D, de la Camara R, Cordonnier C . Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7):803-11. PMC: 5004459. DOI: 10.3324/haematol.2016.144428. View

13.

Teira P, Battiwalla M, Ramanathan M, Barrett A, Ahn K, Chen M . Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427-38. PMC: 4874224. DOI: 10.1182/blood-2015-11-679639. View

14.

Kumar D, Mian M, Singer L, Humar A . An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation. Am J Transplant. 2017; 17(9):2468-2473. DOI: 10.1111/ajt.14347. View

15.

Rosemarie Q, Sugden B . Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. Microorganisms. 2020; 8(11). PMC: 7699388. DOI: 10.3390/microorganisms8111824. View

16.

Wilson E, Goswami J, Baqui A, Doreski P, Perez-Marc G, Zaman K . Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023; 389(24):2233-2244. DOI: 10.1056/NEJMoa2307079. View

17.

Jorgenson M, Descourouez J, Kleiboeker H, Goldrosen K, Schulz L, Rice J . Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard. Transpl Infect Dis. 2022; 24(5):e13864. DOI: 10.1111/tid.13864. View

18.

Herrera S, Aguado J, Candel F, Cordero E, Dominguez-Gil B, Fernandez-Ruiz M . Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of.... Transplant Rev (Orlando). 2023; 37(4):100788. DOI: 10.1016/j.trre.2023.100788. View

19.

Patel S, Knight R, Kuten S, Graviss E, Nguyen D, Moore L . Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial. Am J Transplant. 2019; 19(6):1831-1837. DOI: 10.1111/ajt.15328. View

20.

Natori Y, Humar A, Husain S, Rotstein C, Renner E, Singer L . Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients. Transplantation. 2016; 101(6):1449-1454. DOI: 10.1097/TP.0000000000001338. View